Ischemia Care (ISC) is a clinical stage diagnostic company developing a platform of blood tests for cause of ischemic stroke and TIA, including atrial fibrillation. ISC’s first test, ISCDX, is anticipated to launch in 2017, upon completion of signature validation through the BASE clinical trial (NCT02014896), which has enrolled over 800 subjects at 18 major hospitals. ISCDX, targets the 40% (280,000) of strokes that never have a cause determined, called “cryptogenic”, leading to increased costs and poor outcomes. The technology is based upon RNA expression and supported by 15 years of peer reviewed clinical research that attracted over $5M in Federal funding. ISC was founded by Jeff June, in 2009, and has raised ~$6.4M. In the 2017, ISC will be seeking support for commercial launch/growth and commercialization of subsequent tests.